Biology Reference
In-Depth Information
Myers G, Pavlakis GN. 1992. Evolutionary potential of complex retroviruses. In: Levy JA (ed). The
Retroviridae. New York, Plenum Press, pp 51±105.
Myers G, Kolber B, Wain-Hobson S, Jeang KT, Henderson LE, Pavlakis GN. 1994. Human
Retroviruses and AIDS. A Compilation and Analysis of Nucleic Acid and Amino Acid Sequences.
Los Alamos, NM, Los Alamos National Laboratory.
Ono M, Wada Y, Wu Y, Nemori R, Jinbo Y, Wang H, Lo KM, Yamaguchi N, Brunkhorst B,
Otomo H, Wesolowski J, Way JC, Itoh I, Gillies S, Chen LB. 1997. FP-21399 blocks HIV en-
velope protein-mediated membrane fusion and concentrates in lymph nodes. Nat Biotechnol 15:
343±348.
Pathak VK, Temin HM. 1990a. Broad spectrum of in vivo forward mutations, hypermutations,
and mutational hotspots in a retroviral shuttle vector after a single replication cycle: deletions
and deletions with insertions. Proc Natl Acad Sci USA 87: 6024±6028.
Pathak VK, Temin HM. 1990b. Broad spectrum of in vivo forward mutations, hypermutations, and
mutational hotspots in a retroviral shuttle vector after a single replication cycle: substitutions,
frameshifts, and hypermutations. Proc Natl Acad Sci USA 87: 6019±6023.
Pedroza Martins L, Chenciner N, Wain-Hobson S. 1992. Complex intrapatient sequence variation
in the V1 and V2 hypervariable regions of the HIV-1 gp120 envelope sequence. Virology 191:
837±845.
Perelson AS, Neumann AU, Markowitz M, Leonard JM, Ho DD. 1996. HIV dynamics in vivo:
virion clearance rate, infected cell life span, and viral generation time. Science 271: 1582±
1586.
Rizzuto C, Sodroski J. 2000. Fine de®nition of a conserved CCR5-binding region on the human
immunode®ciency virus type 1 glycoprotein 120 [In Process Citation]. AIDS Res Hum Retro-
viruses 16: 741±749.
Rizzuto CD, Wyatt R, Hernandez-Ramos N, Sun Y, Kwong PD, Hendrickson WA, Sodroski J.
1998. A conserved HIV gp120 glycoprotein structure involved in chemokine receptor binding
[see comments]. Science 280: 1949±1953.
Sakaida H, Hori T, Yonezawa A, Sato A, Isaka Y, Yoshie O, Hattori T, Uchiyama T. 1998.
T-tropic human immunode®ciency virus type 1 (HIV-1)-derived V3 loop peptides directly bind
to CXCR-4 and inhibit T-tropic HIV-1 infection. J Virol 72: 9763±9770.
Salvatori F, Masiero S, Giaquinto C, Wade CM, Brown AJ, Chieco-Bianchi L, De Rossi A. 1997.
Evolution of human immunode®ciency virus type 1 in perinatally infected infants with rapid and
slow progression to disease. J Virol 71: 4694±4706.
Sato H, Kato K, Takebe Y. 1999. Functional complementation of the envelope hypervariable V3
loop of human immunode®ciency virus type 1 subtype B by the subtype E V3 loop. Virology
257: 491±501.
Scarlatti G, Tresoldi E, Bjorndal A, Fredriksson R, Colognesi C, Deng HK, Malnati MS, Plebani
A, Siccardi AG, Littman DR, Fenyo EM, Lusso P. 1997. In vivo evolution of HIV-1 co-receptor
usage and sensitivity to chemokine-mediated suppression. Nat Med 3: 1259±1265.
Shankarappa R, Gupta P, Learn Jr GH, Rodrigo AG, Rinaldo Jr CR, Gorry MC, Mullins JI, Nara
PL, Ehrlich GD. 1998. Evolution of human immunode®ciency virus type 1 envelope sequences
in infected individuals with di¨ering disease progression pro®les. Virology 241: 251±259.
Shankarappa R, Margolick JB, Gange SJ, Rodrigo AG, Upchurch D, Farzadegan H, Gupta P,
Rinaldo CR, Learn GH, He X, Huang XL, Mullins JI. 1999. Consistent viral evolutionary
changes associated with the progression of human immunode®ciency virus type 1 infection. J
Virol 73: 10489±10502.
Shioda T, Levy JA, Cheng-Mayer C. 1992. Small amino acid changes in the V3 hypervariable re-
gion of the gp120 can a¨ect the T-cell line and macrophage tropism of human immunode®ciency
virus type 1. Proc Natl Acad Sci USA 89: 9434±9438.
Sodroski JG. 1999. HIV-1 entry inhibitors in the side pocket. Cell 99: 243±246.
